




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61F 2/06		A1	(11) International Publication Number: WO 99/08624
			(43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/16599		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 August 1998 (11.08.98)			
(30) Priority Data: 08/915,539 15 August 1997 (15.08.97) US			
(71) Applicant: HEARTSTENT CORPORATION [US/US]; 651 Campus Drive, St. Paul, MN 55112 (US).			
(72) Inventors: KNUDSON, Mark, B.; 1309 West Royal Oaks Drive, Shoreview, MN 55126 (US). TWEDEN, Katherine, S.; 1175 Ashley Lane, Mahtomedi, MN 55115 (US).			
(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).		Published With international search report.	

(54) Title: CORONARY ARTERY BYPASS WITH REVERSE FLOW

**(57) Abstract**

An obstructed coronary artery is bypassed by forming a first blood flow path from a left ventricle of the heart to a coronary vein associated with the obstructed coronary artery. A second blood flow path is formed from the obstructed coronary artery to the right ventricle for blood to flow from the left ventricle through the coronary vein to the myocardium and subsequently through the coronary artery to the right ventricle in a blood flow direction opposite a normal blood flow direction in the coronary artery and coronary vein.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## CORONARY ARTERY BYPASS WITH REVERSE FLOW

### I. BACKGROUND OF THE INVENTION

#### 1. Field of the Invention

This invention pertains to a method and apparatus for performing a coronary artery bypass procedure. More particularly, the present invention reverses flow in a portion of a coronary artery and a coronary vein to direct flow from an oxygenated chamber of the heart through the vein in a direction opposite normal flow and from the myocardium through the artery in a direction opposite normal flow and into a reduced pressure chamber of the heart.

#### 2. Description of the Prior Art

Coronary artery disease is the leading cause of premature death in industrialized societies. Numerous techniques have been developed for bypassing an obstructed or diseased coronary artery. Angioplasty attempts to expand an occluded site. Commonly, a balloon-equipped catheter is used to expand an occluded site. A stent may be placed at the expanded site for the purpose of preventing reblockage. Coronary artery bypass grafting uses a harvested blood vessel from the patient to graft a bypass from the aorta to the occluded artery. Such prior art procedures have numerous problems including re-stenosis of angioplasty treated vessels. Grafting techniques are highly traumatic and present other problems.

New methods have been proposed as alternatives to traditional angioplasty and bypass grafting. These methods include providing a direct blood flow path from the left ventricle directly through the heart wall to the coronary artery and are described in U.S. Patent Nos. 5,429,144, dated July 4, 1995; 5,287,861, dated February 2, 1994; and 5,409,019, dated April 25, 1995 (all to Wilk). All of these techniques include providing a stent in the heart

wall to define a direct flow path from the left ventricle of the heart to the coronary artery. The stent is closed during either diastole or systole to block return flow of blood from the coronary artery during the heart's cycle. For example, the '861 patent teaches a stent which collapses to a closed state in response to heart muscle contraction during systole. The '019 patent (particularly Figures 7A and 7B) teaches a rigid stent (i.e., open during systole) with a one-way valve which closes during diastole to block return flow of blood from the coronary artery. Such techniques for interruption of blood flow during either diastole or systole are undesirable since such interruption can result in areas of stagnant or turbulent blood flow. Such areas of stagnation can result in clot formation which can result in occlusion or thrombi breaking loose. Providing direct blood flow from the left ventricle to the coronary artery has been criticized. For example, Munro et al, "The Possibility Of Myocardial Revascularization By Creation of a Left Ventricle Coronary Artery Fistula", 58 *Journal Thoracic and Cardiovascular Surgery*, pgs. 25-32 (1969) shows such a flow path in Fig. 1. Noting a fallen coronary artery flow and other adverse consequences, the authors concluded "that operations designed to revascularize the myocardium direct from the cavity of the left ventricle make the myocardium ischemic and are unlikely to succeed." id at pg. 31.

In addition to the foregoing, techniques have been developed to directly revascularize the myocardium. For example, U.S. Patent No. 5,429,144 to Wilk (Figs. 10-12) teaches passing a stent from either the coronary artery or the left ventricle directly into but not through the myocardium for direct revascularization of the myocardium. However, these techniques are unsuitable. For example, Roque Pifarre, M.D. et al, in "Myocardial Revascularization From the Left Ventricle: a Physiological Impossibility", 19 *Surgical Forum*, 157-159 (1968), concluded that blood flow from the ventricular lumen to the myocardium to artificially create channels is a physiologic impossibility due to pressure differentials. Also,

supplying a flow of blood to the myocardium without adequate drainage of blood from the myocardium can result in heart swelling and edema.

## II. SUMMARY OF THE INVENTION

5        According to the present invention, a method and apparatus are provided for bypassing an obstructed coronary artery. A first blood flow path is formed from a first chamber of the heart containing oxygenated blood. The first blood flow path extends to a coronary vein associated with an obstructed coronary artery. A second blood flow path is formed from the coronary artery  
10    to a second chamber of the heart where the second chamber has a pressure less than a pressure of the first chamber. Blood flows within the vein from the first chamber to the myocardium in a direction opposite to normal vein flow direction. The blood further flows within the coronary artery from the myocardium to the second chamber in a direction opposite to normal arterial  
15    flow direction.

## III. BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a side elevation schematic view of a heart illustrating, in phantom lines, positions of left and right atriums and left and right ventricles  
20    as well as showing partial sectional views of coronary artery and an associated coronary vein which are connected by artificial blood flow paths directly to the right ventricle and left ventricle, respectively;

Fig. 2 is a side section view of the heart taken along line 2-2 of Fig. 1;

Fig. 3 is the view of Fig. 2 showing revascularization utilizing different  
25    coronary arteries and coronary veins than those utilized in Fig. 2; and

Fig. 4 is an alternative embodiment of Fig. 1 showing artificial obstruction of the coronary vein.

#### **IV. DESCRIPTION OF THE PREFERRED EMBODIMENT**

With reference now to the various drawing figures in which identical elements are numbered identically throughout, a description of the preferred embodiment of the present invention will now be provided.

5        With initial reference to Figs. 1 and 2, a heart 10 is schematically shown and includes an exterior heart wall HW and having interior walls HW' with the walls HW, HW' cooperating to define interior chambers including a right atrium RA, a left atrium LA, a right ventricle RV and a left ventricle LV. Internal heart valves are not shown for ease of illustration.

10        A plurality of coronary arteries CA and coronary veins CV are disposed on the exterior of the heart wall HW. Commonly, coronary arteries and coronary veins are disposed on the heart wall in parallel alignment. The coronary arteries provide oxygenated blood to the myocardium of the heart wall. From the myocardium, blood flow returns through the coronary vein  
15 CV. The coronary artery CA has an associated coronary vein CV such that the portion of the myocardium supplied by the coronary artery CA is drained by the coronary vein CV.

Normally, blood from the right atrium flows into the right ventricle and is directed to the lungs for oxygenation. The oxygenated blood flows to the  
20 left atrium and subsequently to the left ventricle for distribution throughout the body. From the left ventricle, the blood flows through the aorta (not shown) and is passed through the coronary arteries flowing in the direction of arrow A representing a normal arterial blood flow direction. After flowing through the myocardium of the heart, the blood returns through the vein  
25 flowing in a normal vein flow direction illustrated by the arrow B for return to the right atrium and a repeat of the aforementioned cycle.

From time to time, the coronary artery may be occluded illustrated by the occlusion 12 in Fig. 1 such that blood flow through the coronary artery CA is impeded or blocked preventing oxygenated blood from reaching the

myocardium served by the coronary artery CA. Such a condition can result in an infarction and other serious complications to the patient.

The present invention uses first and second blood flow conduits, 14, 14a, respectively. The first blood flow conduit 14 has a first end 16 in blood flow communication within the left ventricle LV. The second end 18 of the first conduit 14 is positioned in blood flow communication with the interior of the coronary vein CV. Similarly, the second blood flow conduit 14a has a first end 16a positioned in blood flow communication with the right ventricle RV and a second end 18a positioned within the interior of the coronary artery CA. The first conduit 14 defines a first blood flow path from the left ventricle LV into the coronary vein CV. The second conduit 14a defines a second blood flow path from the coronary artery CA into the right ventricle RV. The second end 18a of the second conduit 14a is positioned within the coronary artery CA at a position downstream of the obstruction 12 relative to the normal arterial flow direction A.

With the structure thus described, it will be noted that the right ventricle is commonly at a lower pressure than the left ventricle. Oxygenated blood flows from the left ventricle LV into the coronary vein CV and flows in a direction B' opposite the normal flow direction B, such that the oxygenated blood flowing in the direction B' flows to the myocardium to provide oxygenated blood to the myocardium. Blood from the myocardium then flows into the coronary artery CA in the direction of arrow A' which is opposite the direction of the normal arterial blood flow direction A. The blood then flows through the conduit 14a into the right ventricle RV where it is then passed to the lungs for reoxygenation.

Through the use of the conduits 14, 14a, the direction of blood flow within the coronary artery CA and coronary vein CV is reversed from the normal flow direction so that oxygenated blood flows from the vein CV to the myocardium and flows through the coronary arteries CA to be reoxygenated. By draining blood from the myocardium through the coronary artery CA,

build up of blood within the myocardium can be avoided reducing edema.

Further, oxygenated blood is provided to the myocardium at all times reducing risk of infarction.

Figure 4 shows an alternative embodiment to Fig. 1 where the coronary  
5 vein CV is artificially occluded upstream (relative to the normal vein flow  
direction B) of the second end 18 of the conduit 14. The occlusion of the  
coronary vein CV can be made by sutures 20 to close the coronary vein CV  
upstream of the conduit 14. The addition of the artificial occlusion by reason  
of the sutures 20 ensures that all blood flow through the conduit 14 flows in  
10 the reverse direction B' with distribution to the myocardium.

Fig. 2 illustrates the present invention where the coronary artery which  
is occluded is part of a coronary artery CA and coronary vein CV pair residing  
in alignment with an interior dividing wall HW' which separates the right  
ventricle RV from the left ventricle LV. In such an application, the conduits  
15 14, 14a are rigid tubes sized to extend from the lower wall of the coronary  
artery CA, and coronary vein CV, and extend into the right ventricle RV and  
left ventricle LV to protrude within the interior of the right ventricle RV and  
left ventricle LV by a distance of about 1-3mm. The tubes 14, 14a may be  
made of any rigid material such as metal, ceramic or polymers which are  
20 sufficiently rigid to resist contractions resulting from the heart wall HW  
during systole such that the tubes 14, 14a remain open to blood flow during  
both systole and diastole.

Fig. 3 illustrates an alternative application where the coronary artery  
CA' and coronary vein CV' are disposed away from the interior dividing wall  
25 HW'. In such an application, the first conduit 14' is sized to pass through the  
heart wall HW into the left ventricle LV with a first end 16' of the conduit 14'  
disposed within the interior of the left ventricle LV and with a second end 18'  
disposed within the coronary vein CV'. The entire length of the conduit 14'  
passes through the heart wall. In order to provide a conduit 14a' from the  
30 coronary artery CA' to the right ventricle RV, the second conduit 14a' has its



first end 16a' in communication with the right ventricle RV and a second end 18a' in communication with the coronary artery CA'. A portion of the conduit 14a' passes through the heart wall HW with a remainder of the conduit 14a' disposed in overlying relation to the heart wall HW and with the second end 5 18a' entering the coronary artery CA' through the side of the coronary artery CA' rather than through the floor of the coronary artery CA' as was illustrated with reference to Fig. 2.

In the embodiments shown, the coronary arteries CA, CA' are shown with conduits 14a, 14a' with their first ends 16a, 16a' in communication with 10 the right ventricle RV. Alternatively, the right ends 16a, 16a' could be provided in blood flow communication with the right atrium RA which is at a lower pressure than the left ventricle LV.

As further alternatives to the above, the conduits 14a, 14a' can connect the coronary artery CA, CA' to the right atrium RA, left atrium LA or the 15 vena cava. Also, multiple second conduits 14a, 14a' can be used to increase drainage.

Having described the present invention and the preferred embodiment, modifications and equivalents of the disclosed concepts may occur to one of ordinary skill in the art. It is intended that such modifications and equivalents 20 shall be included within the scope of the claims which are appended hereto.

## WHAT IS CLAIMED IS:

1. A method for bypassing an obstructed coronary artery having a normal arterial flow direction for supplying blood to a myocardium of a heart and having an associated coronary vein having a normal vein flow direction for removing said blood from said myocardium, said method comprising:
  - forming a first blood flow path from a first chamber of said heart containing oxygenated blood and to said coronary vein;
  - forming a second blood flow path from said coronary artery to a second chamber having a pressure less than a pressure of said first chamber;
  - whereby blood flows within said vein from said first chamber to said myocardium in a direction opposite to said normal vein flow direction and said blood flows within said coronary artery from said myocardium to said second chamber in a direction opposite to said normal arterial flow direction.
2. A method according to claim 1 wherein said first chamber is a left ventricle of said heart.
3. A method according to claim 2 wherein said second chamber is a right ventricle of said heart.
4. A method according to claim 1 further comprising positioning said second blood flow path to enter said coronary artery at a location downstream of an obstruction with said coronary artery relative to said normal arterial flow direction.
5. A method according to claim 1 further comprising obstructing said coronary vein at a location downstream, relative to said normal vein flow

direction, of a location of entry of said first blood flow path into said coronary vein.


6. An apparatus for bypassing an obstructed coronary artery having a normal arterial flow direction for supplying blood to a myocardium of a heart and having an associated coronary vein having a normal vein flow direction for removing said blood from said myocardium, said apparatus comprising:

a first blood flow conduit having a first end in blood flow communication with a first chamber of said heart containing oxygenated blood and said first blood flow conduit having a second end in blood flow communication with said coronary vein;

a second blood flow conduit having a second end in blood flow communication with said coronary artery and said second blood flow conduit having a first end in blood flow communication with a second chamber having a pressure less than a pressure of said first chamber;

whereby blood flows within said vein from said first chamber to said myocardium in a direction opposite to said normal vein flow direction and said blood flows within said coronary artery from said myocardium to said second chamber in a direction opposite to said normal arterial flow direction.

FIG. 1








FIG. 4



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/16599

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 655 548 A (NELSON ET AL) 12 August 1997 see the whole document -----	6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 December 1998

Date of mailing of the international search report

09/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smith, C

# INTERNATIONAL SEARCH REPORT

...ernational application No.

PCT/US 98/16599

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-5  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/16599

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5655548 A	12-08-1997	AU 4352497 A	02-04-1998
		WO 9810714 A	19-03-1998
		US 5824071 A	20-10-1998
<hr/>			

**THIS PAGE BLANK (USPTO)**